In a significant leap forward for therapeutic science, researchers at Cornell University have developed a pioneering method to 'cloak' proteins, enabling their efficient delivery into living cells.
The FDA has granted accelerated approval to Adaptimmune’s Tecelra, a T cell therapy for the treatment of synovial sarcoma when other lines of treatment do not work.
Pfizer will let go of 150 employees at its Sanford, US site that were involved in the development of a gene therapy for Duchenne muscular dystrophy that recently failed in a phase 3 clinical trial.
The fundraising will support the development of the company’s technology platform for silencing RNA (siRNA), which has the potential to enable dosing patients every six months to treat a wide range of conditions.
The contract development and manufacturing organization (CDMO) arm of the Israeli company Pluri will deploy automated and 3D cell expansion technology to produce cell therapies developed by compatriot firm Kadimastem.
Ionis Pharmaceuticals antisense therapy for Angelman syndrome achieved good early safety and efficacy results and the company now plans to advance the therapy to phase 3.
Contract development and manufacturing organizations (CDMOs) perform vital services for the biopharmaceutical industry – a role that is growing as cell and gene therapies gain momentum. Here are five of the top CDMOs bringing advanced therapies toward...
A gene therapy being developed by Lexeo Therapeutics to treat cardiomyopathy caused by Friedreich ataxia, a rare neurodegenerative genetic disease, has achieved good interim results in a phase 1/2 trial.
Integrated DNA Technologies (IDT) is doubling down on its commitment to innovation with the launch of a new 25,000-square-foot synthetic biology facility in Coralville, Iowa.
Thermo Fisher’s cutting-edge ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering comprehensive cold and ultra-cold services.
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been chosen by UMass Chan Medical School to manufacture clinical-grade AAV9-CSA vector using its suspension AAV Curator Platform...
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
Hot on the heels of last year’s EU approval of Hemgenix, the first gene therapy for the blood disorder hemophilia B, the UK and Denmark are the latest European nations to take steps to pay for the treatment.
The US FDA has delayed approval of Rocket Pharmaceuticals’ gene therapy for treatment of a rare immune condition known as leukocyte adhesion deficiency, citing a need for more information about the manufacturing process.
Results from a phase 1/2 clinical trial revealed that PolTREG’s regulatory T cell (Treg) therapy, PTG-007, was able to restore insulin secretion in children with type-1 diabetes.
Described by colleagues as an exceptional leader and champion of equity and diversity, this week's woman in science is Maryam Abdul-Kareem, the general counsel of Arcellx.
Thermo Fisher’s new state-of-the-art ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering a comprehensive range of cold and ultra-cold services.
The Seattle-based company Cyrus Biotechnology has spun out Levitate Bio to offer artificial intelligence (AI)-based protein design software to customers across the biopharma space.
Alvotech of Iceland and STADA Arzneimittel of Germany have extended an existing partnership to co-develop a clinical-stage biosimilar for Prolia and Xgeva, Amgen’s therapies for bone conditions based on the antibody drug denosumab.
Director of cell and gene therapy R&D at Lonza, this week's inspiring female is Inbar who we spoke to about her passion for discovering the future and mentor support sparked her early interest in biology and informed her journey of resiliency.
In spite of their potential to tackle cancer in the long term, CAR-T cell therapies face challenges in terms of pricing, manufacturing and being limited to blood cancer.
Kyverna Therapeutics has unveiled compelling new data for its CAR T-cell therapy, KYV-101, which may revolutionize the treatment of autoimmune diseases.
In what could be a significant leap for scientific research and biopharmaceuticals, DefiniGEN and Atelerix have unveiled a new collaboration that allows in vitro cell models to be shipped internationally without freezing or cryopreservation.
As the BIO International 2024 trade show approaches, industry insiders anticipate a significant focus on partnership discussions, driven by the pressing financial needs of biotech companies rather than the new BIOSECURE act.
Cellular Origins and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a new collaboration to demonstrate universal automation of CGT manufacturing.
EXO Biologics, a clinical-stage biotech specializing in exosome-based therapies, recently announced the successful raising of €16 million in Series A funding.
Life sciences business Cytiva is set to launch its new platform, designed to accelerate the manufacturing process for autologous CAR-T cell therapies. Find out more about the company's priorities, market challenges, expansion plans and more.
Regeneron Pharmaceuticals’ gene therapy for otoferlin-related hearing loss, a genetic cause of deafness, has restored hearing to normal levels in one deaf child within just 24 weeks.
Circio, a biotech firm specializing in circular RNA-based gene therapy, has unveiled two posters showcasing in vivo proof-of-concept for its circVec platform at ASGCT 2024.
Courtney Noah works in scientific affairs at BioIVT and after an amazing biology teacher in grade nine gave her a passion for science, she then followed the same teacher through her education.
Bristol Myers Squibb partners with Repertoire Immune Medicines to develop innovative vaccines aimed at treating autoimmune disorders more selectively and effectively
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable
SK pharmteco has signed an agreement with Ferring Pharmaceuticals, to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical gene therapy Adstiladrin.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
